Τίτλος:
Risk for Venous Thromboembolic Events in Patients With Advanced Urinary Tract Cancer Treated With First-Line Chemotherapy
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
We identified the incidence and risk factors of venous thromboembolism in 335 chemotherapy-treated patients with urothelial cancer. The Khorana risk score did not accurately predict risk for thromboembolic events; on the contrary, history of vascular events was associated with a 3-fold increase of this risk. The role of prophylaxis in this group should be further studied. © 2020 Elsevier Inc.
Background: Venous thromboembolic events (VTEs) frequently occur in cancer patients. Risk assessment models (RAMs) for cancer-associated thrombosis have been proposed. However, advanced urinary tract cancer (aUTC) was not adequately represented in these models. We studied the incidence of VTEs, the risk factors, and the applicability of recently described RAMs. Patients and Methods: Data from 335 patients with aUTC treated with chemotherapy between April 1995 and September 2015 in a single institution were analyzed. Results: A total of 95.2% received platinum-based first-line chemotherapy. Twenty-nine patients (8.7%) experienced VTEs. The 6-, 12-, and 24-month VTE incidence was 7.4% (95% confidence interval [CI], 4.8-10.6), 8.1% (95% CI, 5.4-11.5) and 9.4% (95% CI, 6.4-13.1), respectively. No significant association of VTE incidence with the Khorana risk score was observed. History of vascular event (VTE and/or arterial thromboembolic event) was significantly associated with the development of VTE. Patients with such history had a 6-, 12-, and 24-month VTE incidence of 16.2% (95% CI, 6.6-29.7), 19.2% (95% CI, 8.4-33.3), and 25.2% (95% CI, 12.5-40.1) compared to 6.2% (95% CI, 3.7-9.4), 6.6% (95% CI, 4.1-10), and 7.1% (95% CI, 4.4-10.6) of those who did not. The discriminatory ability of this factor adjusted for leucocyte count, sex, Eastern Cooperative Oncology Group performance status, and type of chemotherapy reached 0.79 (95% CI, 0.71-0.87) compared to the 0.58 (95% CI, 0.49-0.66) for the Khorana risk score. Conclusion: Development of tumor-specific algorithms for the risk of VTEs is advisable. Patients with aUTC and a history of vascular events are at high risk for VTE development, and prophylaxis should be prospectively studied in this group. © 2020 Elsevier Inc.
Συγγραφείς:
Bamias, A.
Tzannis, K.
Dimitriadis, I.
Tsironis, G.
Papatheorodidi, A.-M.
Tsiara, A.
Fragkoulis, C.
Xirokosta, A.
Barbarousi, D.
Papadopoulos, G.
Zakopoulou, R.
Varkarakis, I.
Mitsogiannis, I.
Adamakis, I.
Alamanis, C.
Stravodimos, K.
Papatsoris, A.G.
Dellis, A.E.
Drivalos, A.
Ntoumas, K.
Matsouka, H.
Halvatsiotis, P.
Raptis, A.
Gerotziafas, G.T.
Dimopoulos, M.A.
Περιοδικό:
Clinical Genitourinary Cancer
Εκδότης:
HANLEY & BELFUS-ELSEVIER INC
Λέξεις-κλειδιά:
acenocoumarol; carboplatin; cisplatin; cytotoxic agent; gemcitabine; hemoglobin; low molecular weight heparin; anticoagulant agent; antineoplastic agent, adult; advanced cancer; aged; anticoagulant therapy; Article; cancer chemotherapy; cancer survival; controlled study; dose densification; drug dose regimen; female; follow up; hemoglobin blood level; high risk population; human; incidence; intermediate risk population; leukocyte count; major clinical study; male; overall survival; risk assessment; urinary tract cancer; venous thromboembolism; Greece; middle aged; pathology; prognosis; retrospective study; risk factor; survival rate; urinary tract tumor; venous thromboembolism; very elderly, Adult; Aged; Aged, 80 and over; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Female; Follow-Up Studies; Greece; Humans; Incidence; Male; Middle Aged; Prognosis; Retrospective Studies; Risk Factors; Survival Rate; Urologic Neoplasms; Venous Thromboembolism
DOI:
10.1016/j.clgc.2019.12.021
